Incretin Atlas › Trials › PIONEER 6
PIONEER 6
Semaglutide · T2D at high CV risk
Design
- Molecule(s)
- Semaglutide
- Population
- T2D at high CV risk
- Official title
- A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Registry status
- completed · 2017-01 → 2018-09
- Participants
- 3183
- Registry
- NCT02692716
Cardiovascular and kidney outcomes
PIONEER 6 oral semaglutide 14 mg vs placebo · T2D at high CV risk · n = 3183 · 2019 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE primary First occurrence of CV death (including undetermined causes), nonfatal MI, or nonfatal stroke | 0.79 | 0.57–1.11 | 61 vs 76 | verified |
| Cardiovascular death Death from cardiovascular causes (including undetermined causes) | 0.49 | 0.27–0.92 | 15 vs 30 | verified |
| All-cause death Death from any cause | 0.51 | 0.31–0.84 | 23 vs 45 | verified |
| Myocardial infarction Nonfatal myocardial infarction (first events; fatal MI not separately reported) | 1.18 | 0.73–1.90 | 37 vs 31 | verified |
| Stroke Nonfatal stroke (first events; fatal stroke not separately reported) | 0.74 | 0.35–1.57 | 12 vs 16 | verified |
| Hospitalisation for heart failure Heart failure resulting in hospitalization (first events) | 0.86 | 0.48–1.55 | 21 vs 24 | verified |
| Expanded MACE (MACE + HF hosp. + UA) Expanded composite: death from CV causes, nonfatal MI, nonfatal stroke, unstable angina resulting in hospitalization, or heart failure resulting in hospitalization | 0.82 | 0.61–1.10 | 83 vs 100 | verified |
| Hospitalisation for unstable angina Unstable angina resulting in hospitalization | 1.56 | 0.60–4.01 | 11 vs 7 | verified |
Verbatim quotes (8)
- 3-point MACE · Abstract; Results, Cardiovascular Outcomes; Table 2
Major adverse cardiovascular events occurred in 61 of 1591 patients (3.8%) in the oral semaglutide group and 76 of 1592 (4.8%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.57 to 1.11
- Cardiovascular death · Abstract; Table 2
death from cardiovascular causes, 15 of 1591 patients (0.9%) in the oral semaglutide group and 30 of 1592 (1.9%) in the placebo group (hazard ratio, 0.49; 95% CI, 0.27 to 0.92)
- All-cause death · Abstract; Table 2
Death from any cause occurred in 23 of 1591 patients (1.4%) in the oral semaglutide group and 45 of 1592 (2.8%) in the placebo group (hazard ratio, 0.51; 95% CI, 0.31 to 0.84)
- Myocardial infarction · Abstract; Table 2
nonfatal myocardial infarction, 37 of 1591 patients (2.3%) and 31 of 1592 (1.9%), respectively (hazard ratio, 1.18; 95% CI, 0.73 to 1.90)
- Stroke · Abstract; Table 2
nonfatal stroke, 12 of 1591 patients (0.8%) and 16 of 1592 (1.0%), respectively (hazard ratio, 0.74; 95% CI, 0.35 to 1.57)
- Hospitalisation for heart failure · Results, Cardiovascular Outcomes, paragraph 3; Table 2
First events of heart failure resulting in hospitalization occurred in 21 of 1591 patients (1.3%) and 24 of 1592 (1.5%), respectively (hazard ratio, 0.86; 95% CI, 0.48 to 1.55).
- Expanded MACE (MACE + HF hosp. + UA) · Table 2
Expanded composite outcome§ 83 (5.2) 4.0 100 (6.3) 4.9 0.82 (0.61–1.10)
- Hospitalisation for unstable angina · Table 2
Unstable angina resulting in hospitalization 11 (0.7) 0.5 7 (0.4) 0.3 1.56 (0.60–4.01)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: PIONEER 6. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/pioneer-6/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.